Nanoparticles enhance drug solubility, stability, and bioavailability, improving therapeutic outcomes for GI conditions like IBD through targeted delivery mechanisms. Hydrogel-based systems offer ...

A rise in popularity in glucagon-like peptide 1 receptor agonists such as Ozempic and Wegovy is causing concern in the medical community over potential side effects for various physician specialties, ...

AbbVie is securing its place in an emerging gastrointestinal disease drug field, paying China-based FutureGen Biopharmaceutical $150 million in immediate and near-term fees for rights to an antibody ...

Ironwood Pharmaceuticals, a company whose drug research yielded a blockbuster gastrointestinal disorder drug, has struck a $1 billion deal to acquire VectivBio, a biotech whose lead program brings ...

When used as a weight-loss tool, the glucagon-like peptide-1 (GLP-1) receptor agonists semaglutide (Ozempic) and liraglutide (Saxenda), both sold by Novo Nordisk, raise the odds that patients will ...

Recent technological advances have opened new possibilities for the development of advanced medical devices, including tiny robots that can safely move inside the human body. Some of these systems ...

Among the most recently approved drugs for weight management, glucagon-like peptide 1 (GLP-1) agonists have garnered considerable attention; however, the effects of these drugs on the gastrointestinal ...

Inspired by the jets of water that squids use to propel themselves through the ocean, a team developed an ingestible capsule that releases a burst of drugs directly into the lining of the stomach or ...

NEW YORK (Reuters Health) - Although all of the common strategies protect the upper gastrointestinal tract from the complications of nonsteroidal anti-inflammatory drugs (NSAIDs), popular ...

Bausch Health Cos. and its GI business, Salix Pharmaceuticals, will appeal a U.S. District Court of Delaware decision that found some of its drug patents infringed and invalid. According to an Aug. 10 ...